(PharmaNewsWire.Com, October 06, 2017 ) The report "In Vitro Toxicology Testing Market by Products (Assays) & Services, Toxicity Endpoints & Tests (ADME, Skin, Genotoxicity, Organ Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays, Ex-Vivo), Industry (Pharmaceutical, Cosmetics) - Forecast to 2022", The in vitro toxicology testing market is expected to reach USD 8.74 Billion by 2022 from an estimated USD 6.34 Billion in 2017, at a CAGR of 6.6%. The key factors driving the growth of this market include opposition to animal testing, growing demand for in vitro technology in the European market, new and promising technologies, and increasing R&D expenditure to detect toxicity at an early stage.
Browse 139 Market Data Tables and 32 Figures spread through 253 Pages and in-depth TOC on "In Vitro Toxicology Testing Market by Products (Assays) & Services, Toxicity Endpoints & Tests (ADME, Skin, Genotoxicity, Organ Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays, Ex-Vivo), Industry (Pharmaceutical, Cosmetics) - Forecast to 2022"
Early buyers will receive 10% customization on reports.
By Toxicity Endpoints and Tests, ADME hold the largest market share in 2017
Based on toxicity endpoints and tests of in vitro toxicology testing, the market is subsegmented into ADME, genotoxicity, skin irritation and sensitization, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicities (eco toxicity, endocrine disruption, and reproductive & developmental toxicity). In 2017, the ADME segment is expected to account for the largest share of the global in vitro toxicology testing market owing to its highly reproducible & accurate data and the increasing demand to curb drug toxicity at the drug development phase.
Cell culture technology to hold the largest market share in 2017
Based on technology, the in vitro toxicology testing market is segmented into cell culture technologies, high-throughput technologies, cellular imaging technologies, and toxicogenomics. The toxicogenomics segment is expected to account for the highest CAGR in the global in the vitro toxicology testing market. Toxicogenomics is preferred to elucidate the changes in gene expression in response to toxic exposure and facilitates to identify toxicity pathways.
US expected to hold the largest share of the in vitro toxicology testing market in 2017
US is estimated to account for the largest share among other regions in the in vitro toxicology testing market, followed by Germany and UK. In the Asia Pacific region, China is expected to grow at the highest CAGR during the forecast period.
The major players in the global in vitro toxicology testing market include Cyprotex (An Evotec AG subsidiary, Germany), Covance (A Laboratory Corporations of America Holding’s subsidiary, US), Eurofins Scientific SE (Luxembourg), GE Healthcare (US), Thermo Fisher Scientific (US), SGS SA (Switzerland), Promega Corporation (US), Merck KGaA (Germany), Charles River Laboratories, Inc. (US), and Lonza Group Ltd. (Switzerland), among others.
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street, Suite 2175, Seattle, WA 98101, United States 1-888-600-6441 Email: sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
